The global industry for CAR T-cell therapy in treating Non-Hodgkin's lymphoma is experiencing substantial growth. This phenomenon is fueled by several factors, including growing prevalence of Non-Hodgkin's lymphoma, progresses in CAR T-cell therapy technology, and expanding acceptance by healthcare professionals. The market is divided based on fact